Amrutanjan seeks approval for Independent Directors

Amrutanjan Health Care Limited has issued a postal ballot notice dated May 18, 2026, seeking shareholder approval for the appointment and re-appointment of Independent Directors. The notice has been filed pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and relevant circulars issued by the Ministry of Corporate Affairs (MCA). The company has appointed CDSL to facilitate the remote e-voting process.

Resolutions Proposed

The postal ballot notice covers two special resolutions relating to the composition of the Board's independent directorship. The details of the proposed resolutions are as follows:

S.No.	Description of Resolution	Type of Resolution
1.	Appointment of Mr. Ramaswami Krishnan (DIN: 08562199) as Non-Executive Independent Director for a term of five consecutive years	Special Resolution
2.	Re-appointment of Mr. Swayambunathan Muralidharan (DIN: 09198315) as Non-Executive Independent Director for a second term of five consecutive years	Special Resolution

Remote E-Voting Schedule

The remote e-voting facility is available to members whose names appear on the Register of Members or list of beneficial owners as on the cut-off date of Friday, May 15, 2026. The schedule for the postal ballot is outlined below:

Parameter	Details
Cut-off date for determining voting eligibility	Friday, May 15, 2026
Commencement of remote e-voting	Tuesday, May 19, 2026 at 9.00 A.M.
End of remote e-voting	Thursday, June 18, 2026 at 5.00 P.M.

Key Details

Mr. Ramaswami Krishnan was appointed as an Additional Director by the Board effective May 8, 2026. The Board has recommended his appointment as a Non-Executive Independent Director for a term up to May 7, 2031. Mr. Swayambunathan Muralidharan, whose current tenure expires on June 28, 2026, has been recommended for re-appointment for a second term from June 29, 2026, to June 28, 2031.

The notice has been digitally signed by Gagan Preet Singh, General Manager – Legal, Company Secretary & Compliance Officer. Shareholders may access the postal ballot notice and cast their votes through the company website at www.amrutanjan.com or the CDSL e-voting portal at www.evotingindia.com .

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.23%	-1.27%	+0.58%	-21.69%	-21.96%	-26.37%

Amrutanjan Health Care has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a year-on-year increase in profitability, with total income for the fiscal year rising to INR 52,012.66 lakhs from INR 46,949.50 lakhs in the previous year.

Financial Performance for FY26

For the full year ended March 31, 2026, the company recorded a profit after tax of INR 5,791.78 lakhs, compared to INR 5,083.47 lakhs in the prior year. Revenue from operations grew to INR 50,255.27 lakhs, up from INR 45,181.63 lakhs in FY25. Basic earnings per share (EPS) for the year improved to INR 20.03 from INR 17.58 in the previous year. The results include exceptional items, specifically a lease rent provision of INR 760.50 lakhs and an impact of new Labour Codes amounting to INR 125.17 lakhs for the year.

The following table summarises the full-year financial performance:

Particulars:	Year Ended 31 March 2026 (INR in Lakhs)	Year Ended 31 March 2025 (INR in Lakhs)
Revenue from Operations	50,255.27	45,181.63
Total Income	52,012.66	46,949.50
Total Expenses	43,338.21	40,036.10
Profit Before Tax	7,788.78	6,913.40
Profit After Tax	5,791.78	5,083.47
Basic EPS (INR)	20.03	17.58

Q4 Performance Highlights

For the quarter ended March 31, 2026, Amrutanjan Health Care delivered a strong operational performance. Revenue for the quarter stood at INR 14,976.81 lakhs, compared to INR 13,541.36 lakhs in the same quarter of the previous year. Profit after tax for the quarter was INR 1,619.28 lakhs versus INR 1,517.78 lakhs year-on-year. Notably, EBITDA for the quarter surged to INR 2,862.12 lakhs from INR 2,085.57 lakhs in the year-ago period, reflecting a significant improvement in operating efficiency. The EBITDA margin expanded to 19.12% from 15.40% year-on-year, underscoring improved cost management and operating leverage during the quarter.

The key Q4 metrics are presented below:

Metric:	Q4 FY26	Q4 FY25
Revenue	INR 14,976.81 lakhs	INR 13,541.36 lakhs
Net Profit	INR 1,619.28 lakhs	INR 1,517.78 lakhs
EBITDA	INR 2,862.12 lakhs	INR 2,085.57 lakhs
EBITDA Margin	19.12%	15.40%

Dividend Declaration

The Board of Directors has recommended a final dividend of INR 2.90 per equity share for the financial year 2025-26. This dividend is applicable to 2,89,10,630 shares of INR 1 each fully paid up. If approved by shareholders at the Annual General Meeting, the dividend will be paid within 30 days of the meeting. An interim dividend of INR 1 per share was already paid during the quarter ended March 31, 2026.

Board Appointments and Approvals

The board approved the appointment of Mr. Ramaswami Krishnan (DIN: 08562199) as an Additional Director designated as Non-Executive Independent Director for a period of five years effective from May 8, 2026, subject to shareholder approval. The board also approved the re-appointment of Mr. Muralidharan Swayambunathan (DIN: 09198315) as Non-Executive Independent Director for a second and final term of five consecutive years from June 29, 2026, subject to shareholder approval. Additionally, the board approved the rollout of the revised Second Phase "ESOP 2" of the existing ESOP Scheme and appointed M/s. PKF Sridhar & Santhanam as Internal Auditors for the financial year 2026-2027.

Source: None/Company/INE098F01031/4402ce276dbe4e71.pdf